Inhibikase Therapeutics (IKT) Stock Analysis

What Inhibikase Therapeutics does

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Key metrics

ETFs linked to IKT

Broad-market and Healthcare sector ETFs an investor holding Inhibikase Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IKT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Inhibikase Therapeutics?

Inhibikase Therapeutics trades under the ticker IKT on NASDAQ.

Which exchange is IKT listed on?

IKT is listed on NASDAQ.

What sector does Inhibikase Therapeutics operate in?

Inhibikase Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IKT in a portfolio?

PortView shows IKT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.